The US Food & Drug
Administration has approved
Genentech’s Cotellic tablets
(cobimetinib) for the treatment
of patients with unresectable or
metastatic melanoma with a BRAF
V600E or V600K mutation, in
combination with vemurafenib.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Nov 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.